Sirolimus for Injection (Albumin-bound) Combined With Fulvestrant for HR+/HER2- Advanced/Metastatic Breast Cancer Patients Previously Treated With CDK4/6 Inhibitors
Clinical trial NCT06929325 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT06929325
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2025-04-01
- Primary completion
- 2026-10-01
- Enrollment
- 312
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.